KLRA trades 29% below its IPO high but holds $1.17 billion in cash and carries a $42 analyst consensus price target. Merck's looming Keytruda revenue cliff and Novo Nordisk's need to defend Wegovy dominance make both natural buyers of Kailera's GLP-1 pipeline. Any acquirer secures U.S., European, and Japanese rights but inherits up to $5.7 billion in commercial milestones owed to 19.9% stakeholder Hengrui.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Kailera Therapeutics, Inc. Common Stock didn't make the cut. Grab the names FREE today.
Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap. Shares are down 2.5% on the week and 28.8% since shares began trading in April. Kailera holds $1.17 billion in cash and marketable securities, posted a Q2 net loss of $111.31 million, and has runway into mid-2028.
It is clinical-stage and pre-commercial with no product revenue. Kailera shares a strategic, multi-billion-dollar licensing and co-development partnership with Jiangsu Hengrui Pharmaceuticals. Ribupatide injection (KAI-9531), a GLP-1/GIP dual agonist, anchors the global Phase 3 KaiNETIC program of 4,700+ participants, with data in 2028.
Phase 2b high-dose trial (264 participants) is fully enrolled, with data expected mid-2027. Ribupatide oral enters global Phase 3 in H1 2027; KAI-7535 posts Phase 2 data in 2027; tri-agonist KAI-4729 begins Phase 1 by end-2026. CEO Ron Renaud calls Kailera "well positioned to deliver differentiated treatment options to people living with obesity." Per the Kailera S-1, the Territory excludes China, Hong Kong, Macau and Taiwan: a buyer takes U.S., Europe and Japan while greater China stays with Hengrui.
Kailera has paid $100 million upfront, issued 5,677,603 preferred shares valued at approximately $96.4 million at issuance, and made a $10.0 million technology transfer payment. What remains is up to $200.0 million in clinical and regulatory milestones, up to $5.725 billion in commercial milestones, and tiered royalties ranging from low-single-digit to low-tens percentages of net sales, subject to customary reductions, on a Licensed Product-by-Licensed Product and country-by-country basis. New-form and combination options carry mid-seven or low-eight figure exercise payments; Hengrui manufactures clinical materials on request while Kailera bears Territory costs.
Extract — continue reading at the source.
